Comment
doi: 10.1183/13993003.02323-2019.
Print 2020 Jan.
Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor?
Affiliations
- PMID: 32001500
- DOI: 10.1183/13993003.02323-2019
Item in Clipboard
Comment
Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor?
Eur Respir J.
.
Free article
No abstract available
Conflict of interest statement
Conflict of interest: G. Meyer reports grants and non-financial (travel) support from Leo Pharma, BMS-Pfizer, Stago and Bayer Healthcare, outside the submitted work. Conflict of interest: S. Konstantinides reports grants and personal fees from Boehringer Ingelheim, Daiichi-Sankyo, Bayer AG, Biocompatibles Group UK andActelion, personal fees from BMS-Pfizer and MSD, outside the submitted work.
Comment on
-
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC).Eur Respir J. 2019 Oct 9;54(3):1901647. doi: 10.1183/13993003.01647-2019. Print 2019 Sep. Eur Respir J. 2019. PMID: 31473594 No abstract available.
-
Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor?Eur Respir J. 2020 Jan 30;55(1):1902028. doi: 10.1183/13993003.02028-2019. Print 2020 Jan. Eur Respir J. 2020. PMID: 32001499 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
